[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 41 of about 41
1. Quadros CA, Vasconcelos A, Andrade R, Ramos RS, Studart E, Nascimento G, Trajano A: Good outcome after neoadjuvant chemotherapy and extended surgical resection for a large radiation-induced high-grade breast sarcoma. Int Semin Surg Oncol; 2006;3:18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Good outcome after neoadjuvant chemotherapy and extended surgical resection for a large radiation-induced high-grade breast sarcoma.
  • This article is a case report of a high grade, radio-induced, breast malignant fibrous histiocytoma (undifferentiated high grade pleomorphic sarcoma), which developed in a 44-year old female, seven years after breast conservative surgery and radiotherapy for a T1N0M0 invasive left breast ductal carcinoma.
  • The sarcoma presented as a fast growing tumour, 9.5 cm in the largest diameter, with skin, left breast, chest wall muscle and rib invasion.
  • Neoadjuvant chemotherapy was performed with epirubicin and ifosfamide.
  • Extended radical surgery according to oncological standards and soft tissue reconstruction were carried out.
  • Despite bad prognostic features of high grade and large invasive sarcoma, the patient is currently, after 44 months of follow up, without local recurrence, or metastases, exceeding the 12.8-month mean recurrence period and mortality rate for these tumours larger than 8.1 cm (+/- 1.2 cm) as described in the literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2068-75 [10070313.001]
  • [Cites] Radiology. 2000 Jul;216(1):197-205 [10887248.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3378-83 [11013278.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1238-47 [11230464.001]
  • [Cites] Ann Surg Oncol. 1994 Jan;1(1):66-72 [7834431.001]
  • [Cites] Am J Surg. 2002 Oct;184(4):356-8 [12383902.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1832-40 [12673708.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):856-63 [15981282.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):361-7 [1648044.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):172-80 [11443624.001]
  • (PMID = 16824232.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1538603
  •  go-up   go-down


2. O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP: Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol; 2010 Mar 1;28(7):1232-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy.
  • We report the first long-term outcomes of a cohort of pediatric survivors of HL treated with chemotherapy and low-dose radiation.
  • PATIENTS AND METHODS: Pediatric patients with HL (n = 112) treated at Stanford from 1970 to 1990 on two combined modality treatment protocols were identified.
  • Treatment included six cycles of chemotherapy with 15 to 25.5 Gy involved-field radiation with optional 10 Gy boosts to bulky sites.
  • RESULTS: One hundred ten children completed HL therapy; median follow-up was 20.6 years.
  • Eighteen patients developed one or more SMNs, including four leukemias, five thyroid carcinomas, six breast carcinomas, and four sarcomas.
  • Cumulative incidence of first SMN was 17% (95% CI, 10.5 to 26.7) at 20 years after HL diagnosis.
  • For those with second solid tumors, the mean (+/- SE) 5-year disease-free and overall survival were 76% +/- 12% and 85% +/- 10% with median follow-up 5 years from SMN diagnosis.
  • CONCLUSION: Despite treatment with low-dose radiation, children treated for HL remain at significant risk for SMN.
  • Sarcomas, breast and thyroid carcinomas occurred with similar frequency and latency as found in studies of children with HL who received high-dose radiation.
  • [MeSH-major] Hodgkin Disease / therapy. Neoplasms, Second Primary / epidemiology
  • [MeSH-minor] Adolescent. Adult. Breast Neoplasms / epidemiology. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Incidence. Male. Sarcoma / epidemiology. Survivors. Thyroid Neoplasms / epidemiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20124178.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA094069
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4872329
  •  go-up   go-down


3. Kinderyte R, Alisauskaite L, Juodzbaliene EB, Juozaityte E: [Angiosarcoma of the breast: a case report and literature review]. Medicina (Kaunas); 2006;42(7):580-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Angiosarcoma of the breast: a case report and literature review].
  • Sarcoma of the breast is a rare tumor (makes up 0.5 to 1% of all malignant breast tumors).
  • In literature, only isolated cases of primary angiosarcoma of the breast were described.
  • Secondary angiosarcomas are more frequently diagnosed in women and mostly in patients who underwent breast-conserving surgery and were treated by radiotherapy.
  • In this article a very rare case of angiosarcoma of the breast is presented.
  • The tumor in the breast was diagnosed after breast trauma.
  • After surgery the diagnosis of hematoma was made.
  • After review of histopathology slides the likely diagnosis of angiosarcoma of the breast was made.
  • The effect of chemotherapy and radiotherapy was only partial and short.
  • A patient from the time of diagnosis survived for 8 months.
  • The mean survival of patients with angiosarcoma of the breast, described in literature, ranges from 13 to 22 months, and the treatment in this case most likely could not have an effect on survival of the patient.
  • [MeSH-major] Breast Neoplasms. Hemangiosarcoma
  • [MeSH-minor] Adult. Breast / pathology. Diagnosis, Differential. Female. Humans. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lymphatic Metastasis / diagnosis. Mastectomy, Simple. Prognosis. Radiography, Thoracic. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861841.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


Advertisement
4. Al-Benna S, Poggemann K, Steinau HU, Steinstraesser L: Diagnosis and management of primary breast sarcoma. Breast Cancer Res Treat; 2010 Aug;122(3):619-26
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for breast sarcoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of primary breast sarcoma.
  • Primary sarcoma of the breast is an extremely rare and heterogeneous disease.
  • This article reviews the current literature on the diagnosis and management of breast sarcoma.
  • The optimal treatment of breast sarcoma involves a multidisciplinary team prior to the initiation of treatment.
  • Thus, neoadjuvant chemotherapy should be considered in order to shrink the tumour and help obtain negative surgical margins.
  • Whether chemotherapy is indicated is primarily determined by tumour size.
  • After surgical resection, patients with chemosensitive tumours should undergo additional adjuvant chemotherapy to treat micrometastatic disease.
  • Radiation therapy should be used to improve local control in cases in which the tumour is larger than 5 cm and in cases with positive surgical margins.
  • We propose to treat the patients according to the clinical practice guidelines in use for soft tissue sarcomas and address them to a reference centre for sarcoma.
  • The appropriate treatment of breast sarcoma requires a multidisciplinary team approach necessitating experienced sarcoma surgeons, pathologists, radiotherapists and medical oncologists.
  • Treating rare tumours in the same place should permit us to standardise pathological data and to include patients into multicentric radiotherapy or chemotherapy protocols to improve overall survival.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / therapy. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20480227.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  •  go-up   go-down


5. Alabassi A, Fentiman IS: Sarcomas of the breast. Int J Clin Pract; 2003 Dec;57(10):886-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomas of the breast.
  • Breast sarcomas are rare lesions that can be derived from any of the mammary stromal cells.
  • For all the sarcomas spread is haematogenous rather than lymphatic and treatment is based on wide surgical clearance without axillary surgery.
  • Angiosarcoma is a rare consequence of skin irradiation as part of breast conservation therapy.
  • Radiotherapy is not of value but chemotherapy can be used to palliate women with metastatic disease.
  • [MeSH-major] Breast Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Female. Humans. Mastectomy / methods. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14712891.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 32
  •  go-up   go-down


6. de Mello RA, Figueiredo P, Marques M, Sousa G, Carvalho T, Gervásio H: Concurrent breast stroma sarcoma and breast carcinoma: a case report. J Med Case Rep; 2010;4:414

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent breast stroma sarcoma and breast carcinoma: a case report.
  • INTRODUCTION: Breast cancer is one of the most important health problems in the world and affects a great number of women over the entire globe.
  • This group of tumors rarely presents as bilateral disease and, when it does happen, normally occurs within the same histological type.
  • We report a rare case of concurrent bilateral breast cancer with two different histology types, a breast carcinoma and a breast sarcoma, in a 42-year-old woman referred to our hospital.
  • CASE PRESENTATION: A 42-year-old Caucasian woman admitted to our institute in August 1999, presented with a nodule in the left breast of 3.0 × 2.5 cm, and, in the right breast, one of 1.0 cm, suspected of malignancy and with a clinically negative armpit.
  • Biopsies had revealed invasive mammary carcinoma (right breast) and sarcoma (left breast).
  • A histological study showed an invasive mammary carcinoma degree II lobular pleomorphic type with invasion of seven of the 19 excised axillary nodes in the right breast and, in the left breast, a sarcoma of the mammary stroma, for which the immunohistochemistry study was negative for epithelial biomarkers and positive for vimentin.
  • Later, she was submitted for chemotherapy (six cycles of 75 mg/m2 5-fluorouracil, epirubicin and cyclophosphamide) followed by radiotherapy of the thoracic wall and axillary nodes on the left.
  • Hormone receptors were positive in the tumor of the right breast, and tamoxifen, 20 mg, was prescribed on a daily basis (five years) followed by letrozole, 2.5 mg, also daily (five years).
  • CONCLUSION: The risk of development of bilateral breast cancer is about 1% each year within a similar histological type, but it is higher in tumors with lobular histology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Aug;83(3):384-6 [10917555.001]
  • [Cites] Neoplasma. 2002;49(1):49-54 [12044060.001]
  • [Cites] Radiology. 2003 Mar;226(3):773-8 [12601182.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1055-62 [14981104.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2328-35 [15197194.001]
  • [Cites] Asian J Surg. 2004 Oct;27(4):339-41 [15564192.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5534-41 [16110014.001]
  • [Cites] Surg Today. 2008;38(8):739-42 [18668319.001]
  • [Cites] Curr Oncol Rep. 2008 Jul;10(4):329-37 [18778559.001]
  • [Cites] Pathology. 2009 Jan;41(1):3-17 [19089735.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Aug;17(2):263-71 [2546905.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1545-52 [8336193.001]
  • [Cites] Cancer. 1965 Oct;18(10):1233-43 [5833629.001]
  • [Cites] Cesk Patol. 2009 Apr;45(2):29-34 [19534390.001]
  • (PMID = 21182764.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3022674
  •  go-up   go-down


7. Grenier J, Delbaldo C, Zelek L, Piedbois P: [Phyllodes tumors and breast sarcomas: a review]. Bull Cancer; 2010 Oct;97(10):1197-207
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumors and breast sarcomas: a review].
  • [Transliterated title] Tumeurs phyllodes et sarcomes du sein: mise au point.
  • Phyllodes tumors and sarcomas of the breast are non-epithelial tumors of the breast.
  • The differential diagnosis with a very proliferant fibroadenoma may be difficult.
  • Histological sub-type, type of surgery (definitive or not) and stromal proliferation determine the prognosis.
  • Surgery (often radical) is the standard treatment.
  • Breast sarcomas are even rarer.
  • All histological types exist with a predominance of histiofibrocytome type tumors.
  • Among the various sub-types, angiosarcoma is characterized by a high risk of occurrence in irradiated fields and by a poor prognosis with a high risk of lung metastases.
  • The treatment is mostly based on mastectomy without lymph node dissection given the exceptional flooding axillary.
  • In some situations, a conservative treatment can be discussed, based on tumor size, grade and volume of the breast.
  • Systemic chemotherapy is not a standard but should be discussed in the forms at high risk of relapse (like angiosarcoma).
  • [MeSH-major] Breast Neoplasms / pathology. Phyllodes Tumor / pathology. Sarcoma / pathology
  • [MeSH-minor] Female. Hemangiosarcoma / pathology. Hemangiosarcoma / secondary. Hemangiosarcoma / therapy. Humans. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855241.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


8. Hefny AF, Bashir MO, Joshi S, Branicki FJ, Abu-Zidan FM: Stromal sarcoma of the breast: a case report. Asian J Surg; 2004 Oct;27(4):339-41
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal sarcoma of the breast: a case report.
  • We report a case of a 36-year-old lady who presented with a huge fungating tumour that involved the entire right breast.
  • The tumour was diagnosed histologically as undifferentiated primary stromal tumour of the breast with axillary lymph node metastasis.
  • Stromal sarcomas of the breast lack epithelial participation, and diagnosis of these tumours can be difficult.
  • Genome-wide expression profiling is currently used to determine the cell of origin of most sarcomas.
  • Surgery offers the best therapeutic option.
  • Adjuvant radiotherapy is not very beneficial, while chemotherapy has, to date, no established role in the management of this disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15564192.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Blanchard DK, Reynolds CA, Grant CS, Donohue JH: Primary nonphylloides breast sarcomas. Am J Surg; 2003 Oct;186(4):359-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary nonphylloides breast sarcomas.
  • BACKGROUND: The prevalence of primary breast sarcoma is low, occurring in fewer than 1% of women with breast malignancies.
  • The purpose of this study was to examine the presentation, treatment, and prognosis of patients presenting with these neoplasms.
  • METHODS: This was a retrospective review of patients with a primary breast sarcoma treated at Mayo Clinic, Rochester, Minnesota, between 1975 and 2001.
  • RESULTS: Of the 55 patients, 17 had breast-conserving therapy and 38 women had mastectomy.
  • The types of sarcoma included angiosarcoma (18), malignant fibrous histiocytoma (11), stromal sarcoma (8), liposarcoma (4), leiomyosarcoma (4), dermatofibrosarcoma protuberans (4), osteosarcoma (3), fibrosarcoma (2), and rhabdomyosarcoma (1).
  • Twenty-nine of 53 patients (55%) developed recurrent sarcoma, and 23 patients (43%) died of their disease.
  • Overall median survival of patients with breast sarcoma was 58 months.
  • Patients with angiosarcoma had a poorer outcome than other sarcoma patients.
  • Twelve of 18 patients (67%) died of angiosarcoma, compared with 11 of 32 patients (34%) of all other sarcoma patients combined.
  • Of 34 patients who did not receive adjuvant chemotherapy or radiation, 13 died of their disease (38%), as compared with 10 of 16 patients (63%) who did receive adjuvant therapy.
  • CONCLUSIONS: While primary nonphylloides breast sarcomas are rare tumors, their treatment and prognosis are poor.
  • Adjuvant chemotherapy and radiation did not improve survival in this report.
  • Surgical extirpation remains the only effective treatment.
  • [MeSH-major] Breast Neoplasms. Sarcoma

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14553850.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Pandey M, Mathew A, Abraham EK, Rajan B: Primary sarcoma of the breast. J Surg Oncol; 2004 Sep 1;87(3):121-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sarcoma of the breast.
  • BACKGROUND AND OBJECTIVES: Primary sarcoma occurring in breast is rare and comprises 0.5-1% of all breast neoplasm.
  • Majority of the series include both stromal and cystosarcoma phyllodes, only a few hundred cases of sarcomas other then cystosarcoma are reported.
  • PATIENTS AND METHODS: We carried out a retrospective analysis of 19 patients with primary sarcoma of the breast treated between 1982 and 2002.
  • There were eight cases of angiosarcoma, four cases of spindle cell sarcoma, two each of pleomorphic sarcoma and stromal sarcoma, and one each of malignant fibrous histiocytoma, embryonal rhabdomyosarcoma, and sarcoma (NOS).
  • Two patients received chemotherapy.
  • After a mean follow-up time of 34.5 months (median 25 months), eight patients failed.
  • Failure was local in five, opposite breast in one, and both local and distant in two.
  • CONCLUSIONS: Primary sarcomas of the breast are aggressive tumors.
  • Surgical treatment should consist of at least simple mastectomy.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Child. Disease-Free Survival. Female. Hemangiosarcoma / drug therapy. Hemangiosarcoma / radiotherapy. Hemangiosarcoma / surgery. Histiocytoma, Benign Fibrous / drug therapy. Histiocytoma, Benign Fibrous / radiotherapy. Histiocytoma, Benign Fibrous / surgery. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / radiotherapy. Rhabdomyosarcoma / surgery. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • [CommentIn] J Surg Oncol. 2004 Oct 1;88(1):50-1 [15384090.001]
  • (PMID = 15334638.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Quintas-Cardama A, Fraga M, Antunez J, Forteza J: Primary extramedullary myeloid tumor of the breast: a case report and review of the literature. Ann Hematol; 2003 Jul;82(7):431-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary extramedullary myeloid tumor of the breast: a case report and review of the literature.
  • Primary extramedullary myeloid tumors (PEMMT) are extramedullary proliferations of myeloid cells occurring in the absence of an antecedent myeloproliferative disorder.
  • Breast is an uncommon location for PEMMT and only a few cases have been reported so far in the medical literature.
  • We reviewed all the reported cases of PEMMT of the breast in the English-language literature since 1965.
  • In addition, we present a new case of PEMMT of the breast who presented with a mass in her right breast mimicking a breast malignancy and was initially misdiagnosed as non-Hodgkin's lymphoma.
  • A careful histologic examination with immunohistochemical studies revealed the presence of PEMMT of the breast.
  • Treatment with systemic chemotherapy and local radiotherapy rendered a complete remission.
  • Seventeen cases of PEMMT of the breast were reported in the English literature from 1965 to 2003.
  • Most of the cases were misdiagnosed initially as lymphomas, breast carcinomas, or malignant melanomas.
  • PEMMT of the breast is a poorly recognized entity whose diagnosis frequently challenges both the pathologist and the oncologist.
  • Given the small number of patients reported no optimal treatment has been defined, but systemic chemotherapy similar to that given for acute myeloid leukemia with or without local radiotherapy may result in long remissions and avoid the progression to overt acute myeloid leukemia.
  • [MeSH-major] Breast Neoplasms / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Neoplasm Invasiveness. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12768322.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down


12. Jelić-Puskarić B, Ostojić-Kolonić S, Planinc-Peraica A, Obad-Kovacević D, Kardum-Skelin I, Jaksić B: Myeloid sarcoma involving the breast. Coll Antropol; 2010 Jun;34(2):641-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma involving the breast.
  • Myeloid sarcoma is a tumor mass with extramedullary growth pattern, composed of myeloblasts or immature myeloid cells.
  • The development of myeloid sarcoma may precede or concur with acute or chronic myeloid leukemia (AML or CML) or other myeloproliferative diseases or myelodysplastic syndromes (MDS).
  • Isolated myeloid sarcoma of the breast is very rare.
  • A case is presented of a 25-year-old, previously healthy woman that presented to our department for a palpable node, 5 x 2 cm in size, in the upper medial quadrant of her left breast.
  • In spite of intensive chemotherapy, the patient died within a year of diagnosis.
  • In cases of isolated breast myeloid sarcoma, the diagnosis can be missed if the possibility of myeloid sarcoma is not remembered on differential diagnosis of a breast neoplasm.
  • [MeSH-major] Breast Neoplasms / pathology. Sarcoma, Myeloid / pathology

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20698144.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


13. Tochika N, Kumon M, Ogawa Y, Sugimoto T, Araki K: Stromal sarcoma of the breast with lung metastasis successfully treated by radiotherapy: report of a case. Surg Today; 2000;30(3):282-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal sarcoma of the breast with lung metastasis successfully treated by radiotherapy: report of a case.
  • We report herein the case of a 42-year-old woman in whom a solitary lung metastasis from stromal sarcoma of the breast was effectively treated by radiotherapy.
  • The original breast tumor had been extirpated in a local hospital, and she was subsequently referred to our outpatient clinic for nonsurgical treatment.
  • Pathological examination of the breast tumor had confirmed a diagnosis of stromal sarcoma.
  • Radiation and systemic chemotherapy for the remnant disease were administered at our hospital; however, 8 months later, local recurrence and a solitary lung metastasis were recognized on a chest X-ray.
  • A second lumpectomy of the recurrent breast tumor along with radiation for the lung metastasis and systemic chemotherapy were performed.
  • This case serves to demonstrate the effectiveness of radiotherapy for the treatment of lung metastasis from stromal sarcoma of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Lung Neoplasms / radiotherapy. Lung Neoplasms / secondary. Sarcoma / radiotherapy. Sarcoma / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Mastectomy, Segmental. Mesenchymoma / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer. 1994 Jul 30;1(1):61-64 [11091509.001]
  • [Cites] Cancer. 1962 Mar-Apr;15:418-24 [13867580.001]
  • [Cites] Mo Med. 1972 Aug;69(8):672-4 passim [5049192.001]
  • [Cites] Surgery. 1994 Sep;116(3):505-9 [8079181.001]
  • (PMID = 10752784.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Ramon Y Cajal T, Mazarico J, Lopez Pousa A, Quintana M, Sala N, Altabas M, Sebio A, Robert L, Alonso C, Barnadas A: Clinical features and outcome in primary breast sarcomas (BS): Analysis of a single-institution experience. J Clin Oncol; 2009 May 20;27(15_suppl):e21520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and outcome in primary breast sarcomas (BS): Analysis of a single-institution experience.
  • Controversy remains about local and adjuvant treatment.
  • METHODS: We analyzed clinicopathological variables, treatment and outcome of 33 BS patients treated at our institution from 1966 to 2007.
  • Adjuvant chemotherapy and radiotherapy in 9 and 7 patients.
  • Radical surgery in BS should be always considered as first treatment option.
  • High-grade non-phylodes BS types may be considered for adjuvant chemotherapy although there were non-statistical differences in OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963450.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Moreno-Vega A, Chavarría N, Rubio J, Villandiego I, Estepa R, Gordon M, Salvador J, Jimenez E: Primary breast sarcoma: Clinical and retrospective analysis of cases from Jerez General Hospital, Spain. J Clin Oncol; 2009 May 20;27(15_suppl):e21526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast sarcoma: Clinical and retrospective analysis of cases from Jerez General Hospital, Spain.
  • : e21526 Background: Primary sarcomas of the breast (PBS) are a heterogeneous group of tumors from stromal breast, infrequent (0.1% of BC).
  • Diagnosis and treatment is unclear.
  • Heterogeneous chemotherapy/radiotherapy schedules was evaluated .
  • RESULTS: Seven cases of PBS (1 male/6 female) were reviewed, from 790 BC diagnosed (0.8%): 2 angiosarcomas (AS), 1 malignant fibrous histiocytoma, 2 undifferentiated, one osteoclastic and other spindle-cell sarcoma.
  • Adjuvant therapy was radiation 57.14% pts; and chemotherapy (doxorubicin 4/liposomal doxorubicin 2 pts) in recurrence.
  • CONCLUSIONS: PBS are rare and difficult diagnosis tumors.
  • There are few series published, without prospective studies to evaluate an adequate therapy, diagnosis and valuable prognostic factors.
  • Our incidence was high, but the independent pathology analysis confirmed all histopathological diagnosis.
  • This review included novel IHC and IRM images, considered necessary for diagnosis and personalized treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963456.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. O'Brien MM, Donaldson SS, Whittemore AS, Link MP: Second malignant neoplasms among survivors of pediatric Hodgkin disease treated with low-dose radiation (15-25.5 Gy) and chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):10003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasms among survivors of pediatric Hodgkin disease treated with low-dose radiation (15-25.5 Gy) and chemotherapy.
  • : 10003 Background: Second malignant neoplasms (SMN) are a known complication of Hodgkin disease (HD) treatment.
  • We report the occurrence of SMN among pediatric HD survivors treated at Stanford with chemotherapy and low-dose radiation from 1970 to 1990.
  • METHODS: Patients received 6 cycles of MOPP (mechlorethamine, vincristine, prednisone, procarbazine) with 15-25.5 Gy radiation ± 10 Gy boost or 3 MOPP and 3 ABVD cycles (doxorubicin, bleomycin, vinblastine, dacarbazine) with 15 Gy radiation ± 10 Gy boost.
  • Multivariate analysis was performed with Cox proportional hazards regression using chronological age as the time scale.
  • Four patients developed secondary leukemia.
  • Fifteen patients developed 17 secondary solid tumors (5 thyroid carcinomas, 6 breast carcinomas, 4 sarcomas, 1 bladder paraganglioma, 1 melanoma) at a median of 15.4 years.
  • All solid tumors except the melanoma occurred within or at the margin of radiation fields, ranging in dose from 15-26.5 Gy.
  • Cumulative incidence of any SMN is 17% (95%CI 10.5-26.7) at 20 years following HD diagnosis.
  • In univariate analysis, older age at HD diagnosis (>11 years) and female gender were associated with SMN (p<0.05).
  • CONCLUSIONS: The incidence of SMN in pediatric HD survivors is elevated following treatment with chemotherapy and low-dose radiation.
  • Sarcomas, breast, and thyroid carcinomas occurred with similar frequency and latency as found in studies of HD survivors who received high-dose radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962547.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Hassan S, Adari G: Primary breast sarcoma: case report. East Afr Med J; 2004 Jul;81(7):375-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast sarcoma: case report.
  • Primary breast sarcoma is a rare entity occurring in 0.5% of women with breast malignancy.
  • Like in breast carcinoma, delay in its diagnosis has important clinical and treatment implications.
  • The subject of this report presented at our breast unit with advanced breast lesion months after she noticed a small lump in her right breast.
  • She had no clear diagnosis despite several consultations, in-patient treatments at two facilities in the city, breast ultrasonography, breast mammography and three fine needle aspiration cytology (FNAC) examinations.
  • Histology following wide excision confirmed high-grade primary stromal breast sarcoma.
  • She required adjuvant combination chemotherapy.
  • A combination of diagnostic failures and patient fault caused delay in subject's treatment.
  • Lesion progression during delay which influenced the pattern of physical morbidity, tumour prognosis and need for adjuvant treatment.
  • Embracing the concept of breast care in dedicated breast units may minimise such treatment delays.
  • [MeSH-major] Breast Neoplasms / diagnosis. Sarcoma / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15490711.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Kenya
  •  go-up   go-down


18. Bhattacharjee PK, Ghosh S, Choudhury T, Mitra SK, Banerjee S: Stromal sarcoma of breast: a case report. J Indian Med Assoc; 2000 Apr;98(4):189-90
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal sarcoma of breast: a case report.
  • A 34 years unmarried female was admitted with an ulcerated foul smelling growth in her right breast.
  • On examination the fungating mass measured 17.5 cm x 15 cm in central and lower part of right breast involving the nipple and areola.
  • The ulcer was covered with slough and rest part of the breast appeared bosselated.
  • Her Hb was 4 g/dl and incision biopsy from the margin of the tumour showed histology of sarcoma.
  • Histopathological examination confirmed it was a case of stromal sarcoma of breast.
  • Chemotherapy was started with vincristine, adriamycin and cylophosphamide.
  • [MeSH-major] Breast Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Adult. Breast / pathology. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Mastectomy, Simple

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11016187.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] INDIA
  •  go-up   go-down


19. Bousquet G, Confavreux C, Magné N, de Lara CT, Poortmans P, Senkus E, de Lafontan B, Bolla M, Largillier R, Lagneau E, Kadish S, Lemanski C, Ozsahin M, Belkacémi Y: Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network. Radiother Oncol; 2007 Dec;85(3):355-61
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network.
  • BACKGROUND AND PURPOSE: Breast sarcoma (BS) is a rare tumour.
  • While surgical resection is the primary treatment, the role of radiation therapy (RT) and chemotherapy remains unclear.
  • This study aimed at defining prognostic factors and treatment strategies.
  • A total dose of 50 Gy in 25 fractions was delivered in 50 patients.
  • At the completion of treatment, 89 patients had no residual tumour.
  • RESULTS: After a median follow-up of 64 months, 56 patients developed recurrent disease: 38 presented a local relapse and 37 developed distant metastases.
  • In multivariate analysis, favourable prognostic factors for better local control were: no residual tumour after treatment, no cellular pleomorphism, and histology other than angiosarcoma.
  • For DFS, the five favourable prognostic factors were non-menopausal status, no residual tumour after treatment, non-angiosarcoma histology, absence of tumour necrosis, and grade 1-2 histology.
  • CONCLUSION: While angiosarcoma has the worst prognosis, the outcome of the other types of sarcomas may be worsened by residual tumour after loco-regional treatment and high grade histology, a classical prognostic factor of the other soft tissue sarcomas.
  • During surgical procedure axillary dissection is not mandatory.
  • [MeSH-major] Breast Neoplasms / therapy. Hemangiosarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023492.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Ireland
  •  go-up   go-down


20. Malard Y, De Lara CT, MacGrogan G, Bussières E, Avril A, Picot V, Bui B, Coindre JM: [Primary breast sarcoma. A retrospective study of 42 patients treated at the Bergonié Institute during a 32-year period]. J Gynecol Obstet Biol Reprod (Paris); 2004 Nov;33(7):589-99
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary breast sarcoma. A retrospective study of 42 patients treated at the Bergonié Institute during a 32-year period].
  • [Transliterated title] Sarcomes primitifs du sein: à propos d'une série rétrospective de 42 cas traités à l'Institut Bergonié sur une période de 32 ans.
  • To analyze Primary breast sarcomas (PBS).
  • To investigate treatment and prognostic factors influencing overall survival (OS) and disease-free survival (DFS).
  • RESULTS: The median age at diagnosis was 56.9 years (24-81 years).
  • Surgery was part of the therapeutic strategy in all the patients.
  • CONCLUSION: Careful preoperative multidisciplinary assessment is required before making the decision to treat.
  • [MeSH-major] Breast Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Hemangiosarcoma / drug therapy. Hemangiosarcoma / mortality. Hemangiosarcoma / radiotherapy. Hemangiosarcoma / surgery. Humans. Mastectomy. Middle Aged. Phyllodes Tumor / drug therapy. Phyllodes Tumor / mortality. Phyllodes Tumor / radiotherapy. Phyllodes Tumor / surgery. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15550877.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


21. García Giménez D, García Prado E, Sáenz Rodríguez T, Fernández Arche A, De la Puerta R: Cytotoxic effect of the pentacyclic oxindole alkaloid mitraphylline isolated from Uncaria tomentosa bark on human Ewing's sarcoma and breast cancer cell lines. Planta Med; 2010 Feb;76(2):133-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic effect of the pentacyclic oxindole alkaloid mitraphylline isolated from Uncaria tomentosa bark on human Ewing's sarcoma and breast cancer cell lines.
  • Preparations from Uncaria tomentosa, a South American Rubiaceae, have been used in the Peruvian traditional medicine for the treatment of infective, inflammatory and tumoral processes.
  • Its antiproliferative and cytotoxic effects have been tested on human Ewing's sarcoma MHH-ES-1 and breast cancer MT-3 cell lines, using cyclophosphamide and vincristine as reference controls.
  • The IC (50) +/- SE values were 17.15 +/- 0.82 microM for MHH-ES-1 and 11.80 +/- 1.03 microM for MT-3 for 30 hours, smaller than those obtained for the reference compounds.
  • This action suggests that the pentacyclic oxindole alkaloid mitraphylline might be a new promising agent in the treatment of both human sarcoma and breast cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / drug therapy. Cat's Claw / chemistry. Cell Proliferation / drug effects. Indole Alkaloids / therapeutic use. Plant Extracts / therapeutic use. Sarcoma, Ewing / drug therapy
  • [MeSH-minor] Cell Line, Tumor. Dose-Response Relationship, Drug. Female. Humans. Inhibitory Concentration 50. Phytotherapy. Plant Bark

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart . New York.
  • (PMID = 19724995.001).
  • [ISSN] 1439-0221
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Indole Alkaloids; 0 / Plant Extracts; 0 / mitraphylline
  •  go-up   go-down


22. Breccia M, Petti MC, Fraternali-Orcioni G, Monarca B, Latagliata R, D'Elia GM, Mandelli F, Pileri SA: Granulocytic sarcoma with breast and skin presentation: a report of a case successfully treated by local radiation and systemic chemotherapy. Acta Haematol; 2000;104(1):34-7
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma with breast and skin presentation: a report of a case successfully treated by local radiation and systemic chemotherapy.
  • Granulocytic sarcoma (GS) is a rare extramedullary tumor composed of immature myeloid cells.
  • This primary extramedullary lesion may indeed represent a diagnostic and therapeutic dilemma for both the hematopathologist and oncologist.
  • We describe a case of GS diagnosed in a nonleukemic patient and review the literature regarding the pathologic features and treatment of this condition.
  • [MeSH-major] Leukemia / diagnosis. Leukemia / pathology. Leukemia, Myeloid / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Breast Neoplasms / therapy. Combined Modality Therapy. Female. Humans. Immunophenotyping. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / therapy. Radiotherapy, Adjuvant. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology. Skin Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • [CommentIn] Acta Haematol. 2001;105(2):118 [11408719.001]
  • (PMID = 11111120.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. D'Costa GF, Hastak MS, Patil YV: Granulocytic sarcoma of breast: an aleukemic presentation. Indian J Med Sci; 2007 Mar;61(3):152-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of breast: an aleukemic presentation.
  • Granulocytic sarcoma is a rare extramedullary tumor composed of immature myeloid cells.
  • The breast is an uncommon site of presentation and requires a high index of suspicion for diagnosis.
  • We report such a case in a 45-year-old female, who presented with nontender left breast lump of 6 months' duration.
  • A peripheral smear and bone marrow examination at that time was normal.
  • An H and E diagnosis of lobular carcinoma vs. non-Hodgkin's lymphoma was entertained.
  • Immunostains, however, revealed myeloperoxidase, naphthol AS-D chloroacetate esterase and CD43 positivity, indicating a diagnosis of granulocytic sarcoma.
  • It appears that early initiation of systemic AML-type chemotherapy is beneficial and may delay or avert the development of AML in bone marrow and blood.
  • [MeSH-major] Breast Neoplasms / diagnosis. Leukemia, Myeloid, Acute / diagnosis. Sarcoma, Myeloid / diagnosis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337816.001).
  • [ISSN] 0019-5359
  • [Journal-full-title] Indian journal of medical sciences
  • [ISO-abbreviation] Indian J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD43; 0 / Naphthols; 35245-26-2 / naphthol AS-D chloroacetate; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


24. Trent II JC 2nd, Benjamin RS, Valero V: Primary soft tissue sarcoma of the breast. Curr Treat Options Oncol; 2001 Apr;2(2):169-76
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary soft tissue sarcoma of the breast.
  • Primary soft tissue sarcoma (STS) of the breast is a rare and heterogeneous disease.
  • The optimal treatment of primary STS of the breast can best be determined through multidisciplinary discussions prior to the initiation of therapy.
  • Whether chemotherapy is indicated is primarily determined by tumor size.
  • Thus, neoadjuvant chemotherapy should be considered in order to shrink the tumor and help obtain negative surgical margins.
  • After surgical resection, patients with chemosensitive tumors should undergo additional adjuvant chemotherapy to treat micrometastatic disease.
  • Radiation therapy should be used to improve local control in cases in which the tumor is larger than 5 cm and in cases with positive surgical margins.
  • The appropriate treatment of primary STS of the breast requires a multidisciplinary approach necessitating experienced surgeons, pathologists, radiotherapists, and medical oncologists.
  • [MeSH-major] Breast Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Mastectomy. Mastectomy, Segmental. Neoadjuvant Therapy. Neoplasm Staging. Practice Guidelines as Topic. Survival Analysis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1978 Aug;70(2):211-6 [211844.001]
  • [Cites] J Indian Med Assoc. 1983 Sep;81(5-6):89-91 [6674340.001]
  • [Cites] Major Probl Clin Surg. 1979;5:504-42 [222973.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6 [10097144.001]
  • [Cites] Oncology. 1968;22(4):258-68 [4304245.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2068-75 [10070313.001]
  • [Cites] Radiother Oncol. 1999 Aug;52(2):173-8 [10577703.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] Radiology. 1996 Jan;198(1):121-4 [8539362.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):383-90 [10661345.001]
  • [Cites] Surgery. 1994 Sep;116(3):505-9 [8079181.001]
  • [Cites] Cancer. 1962 Mar-Apr;15:418-24 [13867580.001]
  • [Cites] Ann Surg. 1985 Apr;201(4):527-32 [3977455.001]
  • [Cites] Br J Cancer. 1967 Dec;21(4):635-44 [4294611.001]
  • [Cites] J Med Soc N J. 1972 Mar;69(3):243-6 [4501517.001]
  • [Cites] AJR Am J Roentgenol. 1992 May;158(5):993-5 [1314479.001]
  • [Cites] J Clin Epidemiol. 1995 Apr;48(4):539-44 [7722610.001]
  • [Cites] Arch Pathol Lab Med. 1988 Jul;112(7):752-6 [2838007.001]
  • [Cites] Am J Surg. 1994 May;167(5):477-80 [8185030.001]
  • [Cites] Am J Surg. 1987 Mar;153(3):276-80 [3030151.001]
  • [Cites] Br J Cancer. 1967 Jun;21(2):285-94 [6028082.001]
  • [Cites] Cancer. 1986 Nov 15;58(10):2282-9 [3019505.001]
  • [Cites] Cancer. 1970 Jul;26(1):94-9 [4912763.001]
  • [Cites] Johns Hopkins Med J. 1967 Jan;120(1):33-45 [4289572.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):671-5 [8226163.001]
  • [Cites] Am J Surg Pathol. 1981 Oct;5(7):629-42 [7199829.001]
  • [Cites] Clin Nucl Med. 1998 Sep;23 (9):604-8 [9735983.001]
  • [Cites] Eur J Surg Oncol. 1988 Jun;14(3):241-7 [2836236.001]
  • [Cites] Tumori. 1970 Jan-Feb;56(1):39-46 [4316262.001]
  • [Cites] Cancer. 1977 Oct;40(4):1562-70 [907970.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):361-7 [1648044.001]
  • [Cites] Breast Cancer Res Treat. 1989 Jan;13(1):39-48 [2468372.001]
  • [Cites] Surg Clin North Am. 1996 Apr;76(2):383-92 [8610270.001]
  • [Cites] Cancer. 1980 Jul 15;46(2):368-71 [7190060.001]
  • [Cites] Cancer. 1990 Sep 1;66(5):941-4 [2386920.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):113-9 [10219803.001]
  • [Cites] Cancer. 1965 Oct;18(10):1233-43 [5833629.001]
  • [Cites] Cancer. 1977 Oct;40(4):1577-85 [907972.001]
  • [Cites] Clin Oncol. 1977 Mar;3(1):97-105 [193665.001]
  • [Cites] J Surg Oncol. 1972;4(2):131-47 [4338176.001]
  • [Cites] Am Surg. 1976 Nov;42(11):812-6 [185930.001]
  • [Cites] Am J Surg Pathol. 1992 Jul;16(7):667-74 [1326897.001]
  • [Cites] Neoplasma. 1992;39(6):375-9 [1491728.001]
  • [Cites] Cancer. 1976 Sep;38(3):1402-6 [182356.001]
  • [Cites] Am J Clin Oncol. 1998 Jun;21(3):317-21 [9626808.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2000-3 [6889910.001]
  • [Cites] Plast Reconstr Surg. 1991 Jan;87(1):193-4 [1984266.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2378-84 [9196153.001]
  • (PMID = 12057135.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 51
  •  go-up   go-down


25. Joo M, Lee HK, Kang YK, Kim JH: Granulocytic sarcoma of the breast preceding acute myelogenous leukemia: a case report. J Korean Med Sci; 2000 Aug;15(4):457-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the breast preceding acute myelogenous leukemia: a case report.
  • We report a case of granulocytic sarcoma presented as a recurrent breast tumor in a 42-year-old woman with no history of leukemia.
  • The case was initially diagnosed as malignant lymphoma on a previous biopsy specimen and she refused chemotherapy.
  • At the time of recurrence of the breast tumor, the patient showed full-blown features of leukemia.
  • This case of rare tumor suggests that differential diagnosis should be considered when malignant lymphoma of the breast is detected.
  • [MeSH-major] Breast Neoplasms / diagnosis. Diagnostic Errors. Leukemia, Myeloid, Acute / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adult. Carcinoma, Lobular / diagnosis. Cell Nucleus / ultrastructure. Diagnosis, Differential. Female. Humans. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10983697.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] KOREA (SOUTH)
  • [Other-IDs] NLM/ PMC3054663
  •  go-up   go-down


26. Liu Z, Ballinger JR, Rauth AM, Bendayan R, Wu XY: Delivery of an anticancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres. J Pharm Pharmacol; 2003 Aug;55(8):1063-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delivery of an anticancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres.
  • Intratumoral injection of controlled-release microsphere formulations of anticancer compounds has the potential to selectively increase tumour exposure to drugs.
  • This work aimed to evaluate the therapeutic effect and toxicity of microsphere formulations containing the anticancer drug, doxorubicin, in a murine tumour model.
  • Initial in-vitro studies confirmed the ability of verapamil to enhance the accumulation of both doxorubicin and [(99mTc)]sestamibi, also a P-glycoprotein substrate, in EMT6 murine breast sarcoma cells and a doxorubicin-selected multidrug-resistant variant, EMT6/AR1.0.
  • Ex-vivo studies using confocal microscopy demonstrated release of doxorubicin from microspheres and diffusion of the drug through tissue.
  • Following intratumoral injection of doxorubicin-loaded microspheres, alone or in combination with verapamil-loaded microspheres, the tumour diameter was measured serially as an indication of therapeutic effect, while the weight, appearance, and behaviour of the mice were monitored as an indication of general toxicity.
  • Intratumoral injections of doxorubicin-loaded microspheres were tolerated much better than systemic administration of equivalent drug concentrations.
  • There was a modest (up to 34%) delay of tumour growth compared with groups receiving no treatment or blank microspheres.
  • Controlled-release microsphere formulations of anticancer agents administered intratumorally were an efficient way to deliver high drug doses to the tumour with little systemic toxicity.
  • [MeSH-major] Doxorubicin / administration & dosage. Mammary Neoplasms, Experimental / drug therapy. Microspheres. Sarcoma, Experimental / drug therapy. Verapamil / administration & dosage
  • [MeSH-minor] Animals. Cell Line, Tumor. Delayed-Action Preparations. Dextrans / administration & dosage. Drug Resistance, Neoplasm / drug effects. Drug Resistance, Neoplasm / genetics. Female. Genes, MDR / genetics. Injections. Mice. Mice, Inbred BALB C

  • Hazardous Substances Data Bank. VERAPAMIL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12956895.001).
  • [ISSN] 0022-3573
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 80168379AG / Doxorubicin; CJ0O37KU29 / Verapamil; K3R6ZDH4DU / Dextrans
  •  go-up   go-down


27. Kinoshita T, Yokokawa M, Yashiro N: Multicentric granulocytic sarcoma of the breast: mammographic, sonographic, and MR findings. Clin Imaging; 2006 Jul-Aug;30(4):271-4
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric granulocytic sarcoma of the breast: mammographic, sonographic, and MR findings.
  • A rare case of granulocytic sarcoma (GS) of the bilateral breasts after complete remission of acute myelogenous leukemia is reported.
  • However, MR image was useful to evaluate the response of the chemotherapy and detect the nonpalpable relapse tumor and determine the introduction of the radiation therapy early.
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging. Mammography. Sarcoma, Myeloid / diagnosis. Ultrasonography
  • [MeSH-minor] Female. Humans. Middle Aged. Rare Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16814144.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Arenas M, Rovirosa A, Hernández V, Ordi J, Jorcano S, Mellado B, Biete A: Uterine sarcomas in breast cancer patients treated with tamoxifen. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):861-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine sarcomas in breast cancer patients treated with tamoxifen.
  • Tamoxifen (TMX) has been related with the development of uterine sarcomas.
  • Here we present three new cases of uterine sarcomas in patients with breast cancer treated with TMX and we comment on the outcome of the cases described in the literature.
  • In the past 25 years, 60 uterine sarcomas have been diagnosed and treated in Hospital Clínic.
  • Three patients have previously received TMX 20 mg/day for 3, 5, and 7 years for breast cancer.
  • Uterine sarcoma appeared 5, 5, and 7 years, respectively, after the start of TMX treatment, and all of them had stage I (FIGO) disease.
  • After treatment, the disease progressed in two patients and the third patient is alive having a follow-up of 42 months.
  • The low incidence of uterine sarcomas makes it difficult to establish a relationship with TMX.
  • Nevertheless, looking at the literature data, 20 mg/day of TMX over 1 year could be enough to develop uterine sarcoma; the sarcoma appears mainly during the first 8 years and seem to behave more aggressively.
  • Although only 65 cases have been reported in the past 14 years, a strict follow-up is necessary in patients with breast cancer receiving TMX therapy.
  • [MeSH-major] Adenosarcoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Carcinosarcoma / chemically induced. Neoplasms, Second Primary / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681774.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


29. Teo T, Wee SB: Clinically 'benign' breast lumps: sarcoma in hiding?--Case reports and literature review. Ann Acad Med Singapore; 2004 Mar;33(2):270-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinically 'benign' breast lumps: sarcoma in hiding?--Case reports and literature review.
  • Breast sarcoma is a very rare entity that accounts for less than 1% of all breast malignancies and less than 5% of all soft tissue tumours.
  • Medline was used to search for relevant articles concerning the pathology, treatment modalities and long-term prognosis of patients with this rare illness.
  • We also reviewed soft tissue sarcomas found elsewhere.
  • Despite conflicting reports and lack of clinical studies, we believe that a simple mastectomy will suffice as adequate treatment, hence avoiding the undesirable side effects of chemotherapy or radiotherapy.
  • [MeSH-major] Breast Neoplasms / diagnosis. Sarcoma / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15098648.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Singapore
  • [Number-of-references] 22
  •  go-up   go-down


30. Kijima Y, Yoshinaka H, Higashi M, Yokouchi M, Komiya S, Hisaoka M, Aikou T: Metastatic breast tumor arising from synovial sarcoma: report of a case. Surg Today; 2007;37(3):230-3
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic breast tumor arising from synovial sarcoma: report of a case.
  • We report a case of metastatic breast tumor arising from a synovial sarcoma of the lower limb.
  • A 27-year-old Japanese woman was diagnosed to have synovial sarcoma 14 months prior to finding a mass in her left breast.
  • An excisional biopsy was performed and a metastatic synovial sarcoma to the breast was confirmed.
  • Eight months after the resection of the breast lesion, the patient developed local recurrences in both her knee and breast.
  • A tumor resection of the limb lesion and a simple mastectomy for the huge lesion, which was diagnosed to be a metastatic breast tumor without lymph node metastasis, were performed.
  • After the operation, the patient received adjuvant systemic chemotherapy.
  • To the best of our knowledge, this is only the second reported case of a solitary metastatic breast tumor arising from synovial sarcoma.
  • [MeSH-major] Breast Neoplasms / secondary. Knee. Neoplasm Recurrence, Local / therapy. Sarcoma, Synovial / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Lung Neoplasms / secondary. Mastectomy. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1977 Oct;129(4):673-6 [409241.001]
  • [Cites] Radiol Clin North Am. 1982 Sep;20(3):561-8 [7111707.001]
  • [Cites] Radiology. 1982 Jul;144(2):309-12 [7089284.001]
  • [Cites] J Am Coll Surg. 1994 Jul;179(1):49-53 [8019724.001]
  • [Cites] Br J Cancer. 1965 Dec;19(4):738-43 [5862654.001]
  • [Cites] Urology. 1978 Jun;11(6):641-6 [675936.001]
  • [Cites] J Am Geriatr Soc. 1963 Sep;11:891-901 [14060379.001]
  • [Cites] AJR Am J Roentgenol. 1983 Oct;141(4):685-90 [6604418.001]
  • [Cites] Clin Orthop Relat Res. 1982 Apr;(164):257-60 [6279348.001]
  • [Cites] Cancer. 1972 Jun;29(6):1691-6 [4337956.001]
  • [Cites] Surgery. 1953 Mar;33(3):385-90 [13038624.001]
  • [Cites] Breast J. 2004 Jul-Aug;10(4):372 [15239802.001]
  • [Cites] Oncology. 1990;47(3):257-60 [2342767.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Jul;89(4):251-6 [7315321.001]
  • [Cites] Clin Radiol. 1976 Oct;27(4):463-71 [187368.001]
  • [Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]
  • [Cites] Br J Surg. 1959 Jul;47:54-8 [14441414.001]
  • [Cites] Surg Gynecol Obstet. 1974 Jan;138(1):26-8 [4809000.001]
  • (PMID = 17342363.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


31. Confavreux C, Lurkin A, Mitton N, Blondet R, Saba C, Ranchère D, Sunyach MP, Thiesse P, Biron P, Blay JY, Ray-Coquard I: Sarcomas and malignant phyllodes tumours of the breast--a retrospective study. Eur J Cancer; 2006 Nov;42(16):2715-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomas and malignant phyllodes tumours of the breast--a retrospective study.
  • BACKGROUND: Although most breast cancers are adenocarcinomas of the mammary gland, primary breast sarcomas may also arise from mammary gland mesenchymal tissue.
  • The annual incidence of primary breast sarcoma is low and has been estimated at 45 new cases per 10 million women.
  • Phyllodes tumours represent a specific subset of these breast soft tissue tumours.
  • They are composed of a connective tissue stroma and epithelial elements.
  • Pathological presentation ranges from grade I to malignant phyllodes tumours (grade III) where the stromal component clearly exhibits a sarcoma pattern.
  • MATERIALS AND METHODS: SAPHYR (SArcoma and PHYllode Retrospective) is a retrospective study of the experience of Leon Bérard Cancer Centre (Lyon, France) from 1966 to August 2004.
  • SAPHYR aims to describe the characteristics of primary breast sarcomas and to define potential survival factors to be evaluated in future prospective studies.
  • No survival difference was found between malignant phyllodes (grade III) and other primary breast sarcomas (angiosarcomas excluded).
  • Histology revealed three significantly (p=0.0003) different prognostic groups: phyllodes grade I and II (DFS=57%), angiosarcomas (DFS=7%) and phyllodes grade III and other primary breast sarcomas (DFS=45%).
  • DISCUSSION: Phyllodes tumours and primary breast sarcomas are totally different from epithelial breast cancers and should be considered as a distinct group of rare tumours.
  • The first goal of treatment is to achieve negative margins (R0).
  • We propose to treat the patients according to the clinical practice guidelines in use for soft tissue sarcomas and address them to a reference centre for sarcoma.
  • Treating rare tumours in the same place should permit us to standardise pathological data and to include patients into multicentric radiotherapy or chemotherapy protocols to improve overall survival.
  • [MeSH-major] Breast Neoplasms. Phyllodes Tumor. Sarcoma

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17023158.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Hong RL, Tseng YL, Chang FH: Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study. Ann Oncol; 2000 Mar;11(3):349-53
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: There is lack of effective and safe chemotherapy for advanced hepatocellular carcinoma.
  • Polyethylene glycol-coated (pegylated) liposomal doxorubicin (PLD) has long circulation time and enhanced drug accumulation in the tumor tissues.
  • It has significant activity in Kaposi's sarcoma, breast and ovarian cancers and the acute adverse effects of free drug are reduced.
  • The clearance of drug was unexpectedly higher than in cases with normal liver function (P < 0.05).
  • The tumor had a partial remission and the patient survived nine months after PLD treatment.
  • CONCLUSION: PLD could serve as a safe and effective treatment for hepatocellular carcinoma even in the presence of impaired liver function.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10811504.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Liposomes; 80168379AG / Doxorubicin
  •  go-up   go-down


33. Munitiz V, Rios A, Canovas J, Ferri B, Sola J, Canovas P, Illana J, Parrilla P: Primitive leiomyosarcoma of the breast: case report and review of the literature. Breast; 2004 Feb;13(1):72-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive leiomyosarcoma of the breast: case report and review of the literature.
  • Sarcomas of the breast account for under 1% of breast tumours.
  • Leiomyosarcomas are less common, being a subgroup of sarcomas of the breast.
  • The case of a 58-year-old woman with a leiomyosarcoma 4 cm in diameter in the upper external quadrant of the right breast is presented.
  • The patient underwent a Madden-type modified radical mastectomy and axillary lymphadenectomy.
  • Adjuvant chemotherapy was implemented with Adriamycin (four cycles of 21 days).
  • [MeSH-major] Breast Neoplasms / diagnosis. Leiomyosarcoma / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Humans. Mastectomy. Middle Aged

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14759721.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Scotland
  • [Number-of-references] 24
  •  go-up   go-down


34. Sessa C, Perotti A, Noberasco C, De Braud F, Gallerani E, Cresta S, Zucchetti M, Viganò L, Locatelli A, Jimeno J, Feilchenfeldt JW, D'Incalci M, Capri G, Ielmini N, Gianni L: Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer; 2009 May;45(7):1153-61
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.
  • The combination of trabectedin (T) and doxorubicin (D) was brought into clinical development in soft tissue sarcoma (STS) and advanced breast cancer (ABC) because of its in vitro and in vivo additive anti-tumour effect, the fact that there are no overlapping toxicities and the anti-tumour activity of T in those tumours.
  • The recommended dose--given to 18 patients in total--was 700 microg/m(2) T with 60 mg/m(2) D.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Dioxoles / therapeutic use. Doxorubicin / therapeutic use. Sarcoma / drug therapy. Tetrahydroisoquinolines / therapeutic use
  • [MeSH-minor] Adult. Aged. Alanine Transaminase / metabolism. Aspartate Aminotransferases / metabolism. Drug Administration Schedule. Female. Humans. Liver / drug effects. Liver / enzymology. Middle Aged. Nausea / chemically induced. Neutropenia / chemically induced. Treatment Outcome. Vomiting / chemically induced

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19114300.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; 80168379AG / Doxorubicin; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


35. Schulz U, Gokel JM, Poleska W: Soft tissue sarcomas after radiation treatment for breast cancer. Three case studies and review of literature. Strahlenther Onkol; 2000 Mar;176(3):144-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcomas after radiation treatment for breast cancer. Three case studies and review of literature.
  • AIMS: By means of 3 cases with infield soft tissue carcinomas after radiotherapy for breast cancer, symptoms and therapy are described.
  • Consequences for treatment planning and patient's information before radiotherapy for breast cancer are discussed.
  • PATIENTS: Three of 1,025 patients with breast cancer irradiated from 1984 to 1997 suffered from infield secondary soft tissue sarcomas.
  • Two patients had been treated with breast-conserving therapy (computerized planning, 50 Gy to reference point, 5 times 2 Gy/week, 5-MV photons), 1 patient received a local boost dose of 15 Gy (10-MeV electrons), patient 3 radiotherapy of the thoracic wall and regional lymph nodes after mastectomy using 12-MeV electrons (thoracic wall) and 5-MV photons (lymph node areas) to 50 Gy, 5 times 2 Gy/week.
  • No adjuvant chemotherapy was given.
  • All sarcomas were very extensive, all patients died from local progression and/or distant failure after 17, 13 and 12 months.
  • RESULTS: The incidence of spontaneous sarcomas of the breast is about 0.06%, after operation and radiotherapy 0.09 to 0.45%.
  • CONCLUSIONS: Secondary soft tissue sarcomas are very rare, but familiar complications of radiotherapy.
  • Only early diagnosis leads to a chance for cure.
  • Because of unclear correlations to the treatment parameters and rareness of this event, in our opinion no regular information to the patient receiving radiotherapy for breast cancer is mandatory.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Carcinoma, Ductal, Breast / radiotherapy. Neoplasms, Radiation-Induced / etiology. Sarcoma / etiology. Soft Tissue Neoplasms / etiology
  • [MeSH-minor] Aged. Fatal Outcome. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy Dosage. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10742836.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] GERMANY
  • [Number-of-references] 21
  •  go-up   go-down


36. Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF: Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther; 2010 Nov-Dec;23(6):651-61
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach.
  • The combination of electroporation with the administration of otherwise low-permeant cytotoxic drugs is known as electrochemotherapy (ECT).
  • The two most commonly used drugs are bleomycin and cisplatin.
  • ECT has already been proven to be effective in diverse tumor histotypes, including melanoma and basal and squamous cell carcinoma, Kaposi sarcoma, and breast cancer, also in those cases nonresponding to classical chemotherapies or other loco-regional treatment modalities, with a good safety profile.
  • ECT can be proposed as loco-regional therapy for disseminated cutaneous and subcutaneous tumor lesions as alternative treatment modality to conventional therapies or as palliative care, in order to improve patients' quality of life.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Electrochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Humans. Skin / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley Periodicals, Inc.
  • (PMID = 21054709.001).
  • [ISSN] 1529-8019
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


37. Gambini D, Visintin R, Locatelli E, Galassi B, Bareggi C, Runza L, Onida F, Tomirotti M: Paclitaxel-dependent prolonged and persistent complete remission four years from first recurrence of secondary breast angiosarcoma. Tumori; 2009 Nov-Dec;95(6):828-31
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel-dependent prolonged and persistent complete remission four years from first recurrence of secondary breast angiosarcoma.
  • Among angiosarcomas, radiation-induced breast sarcomas (RIBS) represent a well-known entity generally characterized by a poor outcome, especially in patients with advanced disease.
  • Treatments with demonstrated activity against sarcomas include ifosfamide-based regimens and, more recently, taxane derivatives.
  • We report a case of a patient having a secondary breast angiosarcoma recurring early after surgery, who achieved complete remission following treatment with weekly paclitaxel.
  • After 4 years of maintenance therapy, with an interval between consecutive administrations of no longer than 3 weeks, the patient is still in complete remission.
  • A locoregional recurrence was documented twice during this period, the first as a consequence of a brief treatment interruption and the second because of a treatment delay.
  • Nonetheless, in both instances a new complete remission was rapidly achieved with the resumption of the same treatment, without evidence of any significant adverse effects.
  • We discuss the highly unusual behavior of this malignancy and the possible role of the two different mechanisms of action of paclitaxel-antiangiogenic versus cytotoxic-depending on the schedule of administration, with evidence of "false" drug-resistance.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / drug therapy. Hemangiosarcoma / drug therapy. Mastectomy, Segmental. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Schedule. Female. Humans. Neoplasms, Second Primary / drug therapy. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210253.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


38. Rolston KV, Frisbee-Hume SE, Patel S, Manzullo EF, Benjamin RS: Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support Care Cancer; 2010 Jan;18(1):89-94
MedlinePlus Health Information. consumer health - Fever.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients.
  • Twenty-one evaluable patients were enrolled, with sarcoma and breast cancer being the predominant underlying neoplasms.
  • One patient with unexplained fever and persistent neutropenia required hospitalization and responded to alternative therapy.
  • [MeSH-major] Anti-Infective Agents / therapeutic use. Aza Compounds / therapeutic use. Fever / etiology. Neutropenia / drug therapy. Quinolines / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Support Care Cancer. 2004 Sep;12(9):657-62 [15185134.001]
  • [Cites] Clin Infect Dis. 2002 Mar 15;34(6):730-51 [11850858.001]
  • [Cites] J Support Oncol. 2008 May-Jun;6(5):219-20 [18551857.001]
  • [Cites] Diagn Microbiol Infect Dis. 2002 Oct;44(2):187-94 [12458127.001]
  • [Cites] Cancer. 1993 Jun 1;71(11):3640-6 [8490912.001]
  • [Cites] Support Care Cancer. 2008 Sep;16(9):1017-23 [18197434.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2006 Aug;25(8):537-40 [16896825.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2629-35 [15856427.001]
  • [Cites] Clin Infect Dis. 2006 Feb 15;42(4):533-40 [16421798.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3038-51 [10944139.001]
  • [Cites] Am J Med. 1986 Jul 28;81(1A):11-26 [3526877.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):273-7 [16435377.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2489-94 [16628654.001]
  • [Cites] Pediatr Blood Cancer. 2007 Oct 15;49(5):682-6 [17253640.001]
  • [Cites] J Antimicrob Chemother. 2006 Oct;58(4):891-4 [16880172.001]
  • [Cites] Clin Infect Dis. 1999 Sep;29(3):515-21 [10530438.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4129-34 [16943529.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Feb;6(2):122-74 [18319048.001]
  • [Cites] J Antimicrob Chemother. 2004 Jul;54(1):29-37 [15201227.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):316-22 [1732432.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):126-34 [10391572.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):606-11 [18235119.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):422-6 [15937905.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):43-9 [12838298.001]
  • [Cites] Diagn Microbiol Infect Dis. 2003 Oct;47(2):441-9 [14522520.001]
  • [Cites] Am J Med. 1995 Mar;98(3):224-31 [7872337.001]
  • (PMID = 19387695.001).
  • [ISSN] 1433-7339
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Aza Compounds; 0 / Fluoroquinolones; 0 / Quinolines; U188XYD42P / moxifloxacin
  •  go-up   go-down


39. Yerushalmi R, Nordenberg J, Beery E, Uziel O, Lahav M, Luria D, Fenig E: Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro. Exp Oncol; 2007 Jun;29(2):126-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Little is known about the interaction of novel anticancer drugs with other treatment modalities.
  • THE AIM of this study was to examine the effect of combining imatinib mesylate (STI-571) with radiation or cisplatin on the survival of two human solid tumor cell lines - SKNMC cells derived from Ewing sarcoma and breast cancer MCF-7 cells.
  • A similar effect was observed in human MCF-7 breast cancer cells.
  • CONCLUSION: STI-571 improves the outcome of cisplatin or irradiation treatment in vitro.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Breast Neoplasms / drug therapy. Cisplatin / pharmacology. Piperazines / pharmacology. Pyrimidines / pharmacology. Sarcoma, Ewing / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Benzamides. Blotting, Western. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Synergism. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Fluorescent Dyes / metabolism. Humans. Imatinib Mesylate. In Vitro Techniques. Inhibitory Concentration 50. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt / metabolism. Rhodamines / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704745.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Fluorescent Dyes; 0 / Piperazines; 0 / Pyrimidines; 0 / Rhodamines; 2609-88-3 / lissamine rhodamine B; 8A1O1M485B / Imatinib Mesylate; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


40. Sabino MA, Ghilardi JR, Jongen JL, Keyser CP, Luger NM, Mach DB, Peters CM, Rogers SD, Schwei MJ, de Felipe C, Mantyh PW: Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res; 2002 Dec 15;62(24):7343-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several tumor types including sarcomas and breast, prostate, and lung carcinomas grow in or preferentially metastasize to the skeleton where they proliferate, and induce significant bone remodeling, bone destruction, and cancer pain.
  • To begin to define the role COX-2 plays in driving bone cancer pain, we used an in vivo model where murine osteolytic 2472 sarcoma cells were injected and confined to the intramedullary space of the femur in male C3HHeJ mice.
  • [MeSH-major] Bone Neoplasms / complications. Bone Neoplasms / drug therapy. Cyclooxygenase Inhibitors / pharmacology. Isoenzymes / antagonists & inhibitors. Osteosarcoma / complications. Osteosarcoma / drug therapy. Pain / drug therapy
  • [MeSH-minor] Animals. Cell Division / drug effects. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Disease Models, Animal. Hyperostosis / drug therapy. Hyperostosis / enzymology. Hyperostosis / pathology. Male. Mice. Mice, Inbred C3H. Neurons, Afferent / drug effects. Neurons, Afferent / physiology. Osteoclasts / cytology. Osteoclasts / drug effects. Osteoclasts / pathology. Prostaglandin-Endoperoxide Synthases. Spinal Cord / drug effects. Spinal Cord / physiopathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12499278.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA11986; United States / NIDCR NIH HHS / DE / DE00270; United States / NIDCR NIH HHS / DE / DE07288; United States / NINDS NIH HHS / NS / NS23970
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


41. Donald S, Verschoyle RD, Greaves P, Colombo T, Zucchetti M, Falcioni C, Zaffaroni M, D'Incalci M, Manson MM, Jimeno J, Steward WP, Gescher AJ: Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma. Int J Cancer; 2004 Oct 10;111(6):961-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma.
  • ET-743, an experimental antitumor drug with promising activity in sarcoma, breast and ovarian carcinoma, is currently under phase 2 clinical evaluation.
  • We tested the hypothesis that indole-3-carbinol (I3C), the hydrolysis product of glucosinolates occurring in cruciferous vegetables, may protect against ET-743-induced hepatotoxicity in the female Wistar rat, the animal species with the highest sensitivity toward the adverse hepatic effect of this drug.
  • I3C should be investigated as a hepatoprotectant in patients who receive ET-743 therapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Antioxidants / pharmacology. Dioxoles / adverse effects. Indoles / pharmacology. Isoquinolines / adverse effects. Liver / drug effects. Liver / pathology

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15300810.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antioxidants; 0 / Dioxoles; 0 / Indoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; C11E72455F / indole-3-carbinol
  •  go-up   go-down






Advertisement